Form 4: Arcutis CFO Latha Vairavan Executes Tax-Related Stock Sale

Arcutis Biotherapeutics CFO Latha Vairavan sold 435 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Summary

• Latha Vairavan, SVP and Chief Financial Officer of Arcutis Biotherapeutics, Inc., sold 435 shares of common stock.
• The transaction occurred on May 11, 2026, at a price of $21.05 per share.
• The sale was conducted to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person retains beneficial ownership of 85,978 shares of common stock.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a discretionary divestment.

Positives

• The sale was non-discretionary, specifically executed to satisfy tax obligations rather than reflecting a change in management sentiment regarding company prospects.

Negatives

• Reduction in direct equity holdings by a key executive, though the impact is minimal (435 shares).

Risks

• None identified; this is a routine administrative transaction related to compensation tax requirements.

Future Outlook

Not applicable; this is a historical disclosure of an insider transaction.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Industry Context

StockSavvy.ai notes that routine 'sell-to-cover' transactions by executives are standard industry practice for managing tax liabilities arising from equity compensation and generally do not signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation tax management.
• The use of a Rule 10b5-1 plan is a best-practice approach to mitigate concerns regarding insider trading.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was small and related to tax compliance.

Next Steps

• None; this is a completed transaction disclosure.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, CFO, Equity Compensation